Prices are updated after-hours

alzheimer

ALTERITY THERAPEUTICS LTD

PRNAF | $0.0002 -90.0% 11450.0% 0

(0.0% 1d) (0.0% 1m) (-95.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (192.0% volume)
Earnings Calendar:
Market Cap: $ 14,901,366
http://www.pranabio.com
Sec Filling | Patents | n/a employees

(AU) Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

parkinson alzheimer neurodegenerative alzheimer’s

add to watch list Paper trade email alert is off

Quince Therapeutics Inc

QNCX | $1.06 0.95% 0.94% 58K

Professional, Scientific, and T...

(0.0% 1d) (-11.7% 1m) (-31.6% 1y) (0.0% 2d) (0.0% 3d) (6.0% 7d) (-40.72% volume)
Earnings Calendar: 2023-05-10
Market Cap: $ 45,808,147
https://www.cortexyme.com
Sec Filling | Patents | 38 employees

Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.

animals alzheimer alzheimer’s pathogens

add to watch list Paper trade email alert is off

YUMANITY THERAPEUTICS, INC.

KA A | $0.6201 17.67% 15.01% 820K

Manufacturing

(0.0% 1d) (13.4% 1m) (-84.2% 1y) (0.0% 2d) (0.0% 3d) (34.0% 7d) (67.77% volume)
Earnings Calendar:
Market Cap: $ 6,797,821
https://www.proteostasis.com
Sec Filling | Patents | 45 employees

(US) Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company's most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson's disease. Yumanity's drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity's pipeline consists of additional programs focused on Lewy body dementia, multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.

treatment dementia biopharma com alzheimer's disease parkinson pharma arm drug candidate system ytx-7739 disease cel cov alzheimer's gen drug discovery parkinson's tiona alzheimer als rapid program therapeutics neurodegenerative pot phase 1 potential tempo sclerosis platform rap alzheimer’s

add to watch list Paper trade email alert is off

Neurotrope, Inc.

NTRP | $2.76 -10.93% 1.4K

Health Technology

(0.0% 1d) (-31.7% 1m) (-33.6% 1y) (0.0% 2d) (0.0% 3d) (-2.0% 7d) (280.37% volume)
Earnings Calendar:
Market Cap: $ 2,153,967
http://www.neurotropebioscience.com
Sec Filling | Patents | 7 employees

Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY.

neurodegenerative alzheimer treatment alzheimer’s

add to watch list Paper trade email alert is off

Acumen Pharmaceuticals Inc

ABOS | $3.135 -0.48% -0.48% 480K

Professional, Scientific, and T...

(0.0% 1d) (-26.4% 1m) (-17.2% 1y) (0.0% 2d) (0.0% 3d) (-9.8% 7d) (55.72% volume)
Earnings Calendar: 2024-03-25
Market Cap: $ 188,350,104
https://www.acumenpharm.com
Sec Filling | Patents | 2021 employees

Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.

alzheimer alzheimer’s

add to watch list Paper trade email alert is off

Alzamend Neuro Inc

ALZN | $0.6755 -0.23% 48K

Professional, Scientific, and T...

(0.0% 1d) (-31.7% 1m) (17.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (68.9% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 4,638,554
https://alzamend.com/
Sec Filling | Patents | 3 employees

(United States) Alzamend Neuro is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s disease. With its product candidates, the company aims to bring treatments or cures to market at a reasonable cost as quickly as possible. Its current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of its product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

treatment msa vaccine t-cell lithium alzheimer neurodegenerative alzheimer’s

add to watch list Paper trade email alert is off

Vaxxinity, Inc.

VAXX | $0.258 -45.81% -84.53% 5.7M

(0.0% 1d) (-59.3% 1m) (-85.4% 1y) (0.0% 2d) (0.0% 3d) (-35.7% 7d) (614.57% volume)
Earnings Calendar: 2023-03-16
Market Cap: $ 29,121,376
https://vaxxinity.com
Sec Filling | Patents | 2021 employees

Vaxxinity are passionate about delivering transformational, science-led innovation that is distinctly accessible for all. Alzheimer’s, Parksinon’s, COVID-19 and other diseases don’t discriminate based on where you live or how much you make, and Vaxxinity believes medicine shouldn’t either.

alzheimer alzheimer’s covid

add to watch list Paper trade email alert is off

Silo Pharma, Inc.

SILO | $1.96 -0.81% -0.82% 58K

Finance and Insurance

(0.0% 1d) (3.1% 1m) (-3.4% 1y) (0.0% 2d) (0.0% 3d) (1.5% 7d) (295.24% volume)
Earnings Calendar:
Market Cap: $ 5,573,523

Sec Filling | Patents | 1 employees

silo pharma inc. (nasdaq: silo), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder, fibromyalgia, alzheimer’s disease, parkinson’s disease, and other rare neurological disorders. silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry. silo is committed to developing innovative solutions to address a variety of underserved conditions. combining silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space. silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization.

alzheimer’s

add to watch list Paper trade email alert is off

Anavex Life Sciences Corp.

AVXL | $3.69 -2.38% -2.72% 1.1M

Health Technology

(0.0% 1d) (-19.1% 1m) (-53.1% 1y) (0.0% 2d) (0.0% 3d) (-9.6% 7d) (-34.81% volume)
Earnings Calendar: 2024-02-06
Market Cap: $ 302,995,166
http://www.anavex.com
Sec Filling | Patents | 16 employees

(US) Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

neurodegenerative alzheimer nervous system parkinson treatment alzheimer’s

add to watch list Paper trade email alert is off

Longeveron LLC - Class A

LGVN | $1.92 0.0% 480K

(0.0% 1d) (364.6% 1m) (-34.8% 1y) (0.0% 2d) (0.0% 3d) (-10.5% 7d) (5.66% volume)
Earnings Calendar: 2024-03-08
Market Cap: $ 6,403,770
https://www.longeveron.com
Sec Filling | Patents | 12 employees

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.

ceiling respiratory t-cell alzheimer alzheimer’s metabolic

add to watch list Paper trade email alert is off

NeuroSense Therapeutics Ltd.

NRSN | News | $1.33 -6.34% -6.77% 350K

(0.0% 1d) (-25.8% 1m) (-33.2% 1y) (0.0% 2d) (0.0% 3d) (-15.6% 7d) (192.57% volume)
Earnings Calendar:
Market Cap: $ 20,750,716
https://www.neurosense-tx.com
Sec Filling | Patents | n/a employees

NeuroSense Therapeutics is a clinical-stage biopharmaceutical company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases. NeuroSense was founded in 2017 by Alon Ben-Noon, following a chance meeting with Shay Rishoni, an ALS patient. During this meeting, Alon was inspired by Shay, who served as the CEO of a non-profit organization for ALS. Despite Shay not having a physical voice, therefore communicating via eye movement and computer software, the connection was instant. Shay detailed his activities in the ALS field, and described the efforts that are being made to solve the ALS puzzle, leading Alon to team up with world-renowned scientists and colleagues in order to research and develop an effective drug for ALS patients, bringing about the establishment of NeuroSense. To date, the company has commenced with a breakthrough treatment for ALS that will halt, or significantly delay disease progression, as well as developments for Alzheimer’s and Parkinson’s diseases. NeuroSense is focused on creating a combined therapeutic strategy, targeting multiple pertinent mechanisms in these complex diseases. Its research team and advisory board members are multidisciplinary professionals who have many years of experience with drug development and clinical programs, as well as personal connections to neurodegenerative diseases. Their collective expertise and background enable us to move in a fast and efficient manner to achieve its goals. NeuroSense is currently preparing for a phase 2b/3 clinical trial using PrimeC in patients with ALS. NeuroSense is also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. Additionally, NeuroSense is studying the mechanisms of action and relevant biomarkers for these diseases.

israel als treatment profitable communication computational parkinson alzheimer neurodegenerative alzheimer’s ycombinator

add to watch list Paper trade email alert is off

Alector, Inc.

ALEC | $5.18 1.77% 1.74% 350K

Health Technology

(0.0% 1d) (-13.4% 1m) (-19.8% 1y) (0.0% 2d) (0.0% 3d) (1.6% 7d) (-25.44% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 495,981,162
http://www.alector.com
Sec Filling | Patents | 121 employees

(US) Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

neurodegenerative alzheimer parkinson al002 msa treatment alzheimer’s

add to watch list Paper trade email alert is off

Annovis Bio, Inc.

ANVS | $11.49 14.22% 0.0% 320K

Health Technology

(0.0% 1d) (-3.4% 1m) (-22.4% 1y) (0.0% 2d) (0.0% 3d) (16.6% 7d) (42.85% volume)
Earnings Calendar:
Market Cap: $ 126,519,826
http://www.annovisbio.com
Sec Filling | Patents | 2 employees

(US) Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.

neurodegenerative alzheimer parkinson alzheimer’s

add to watch list Paper trade email alert is off

Annexon, Inc.

ANNX | $4.55 -0.22% -0.44% 1.2M

Health Technology

(0.0% 1d) (-31.6% 1m) (-20.2% 1y) (0.0% 2d) (0.0% 3d) (-0.4% 7d) (0.28% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 356,579,400
http://www.annexonbio.com
Sec Filling | Patents | 24 employees

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in South San Francisco, CA.

sclerosis eye multiple sclerosis alzheimer parkinson alzheimer’s

add to watch list Paper trade email alert is off

CohBar, Inc.

CWBR | $0.9003 -11.88% 360

Health Technology

(0.0% 1d) (18.4% 1m) (-50.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-70.82% volume)
Earnings Calendar: 2023-03-28
Market Cap: $ 2,617,105
http://www.cohbar.com
Sec Filling | Patents | 13 employees

CohBar, Inc. engages in the research and development of mitochondria-based therapeutics. It focuses on treatments of diseases, which include diabetes, obesity, fatty liver disease and non-alcoholic steatohepatitis, cancer, Alzheimer's disease, and atherosclerosis. The company was founded by Nir Barzilai, Pinchas Cohen, David Sinclair, John Amatruda, and Laura Cobb on October 19, 2007 and is headquartered in Menlo Park, CA.

cancer diabetes diabetic liver alzheimer mitochondrial dysfunction liver disease treatment alzheimer’s

add to watch list Paper trade email alert is off

Cyclo Therapeutics Inc - Class A

CYTH | $1.26 8.62% 7.94% 84K

Professional, Scientific, and T...

(0.0% 1d) (-11.9% 1m) (57.5% 1y) (0.0% 2d) (0.0% 3d) (5.0% 7d) (46.45% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 36,181,832
https://www.cyclotherapeutics.com
Sec Filling | Patents | 8 employees

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development.

cholesterol genetic alzheimer alzheimer’s

add to watch list Paper trade email alert is off

India Globalization Capital Inc.

IGC 4 | $0.4451 -9.16% 4.02% 650K

Health Technology

(0.0% 1d) (12.5% 1m) (34.3% 1y) (0.0% 2d) (0.0% 3d) (-23.7% 7d) (5.16% volume)
Earnings Calendar:
Market Cap: $ 29,738,417
http://www.igcinc.us
Sec Filling | Patents | 50 employees

India Globalization Capital, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications such as Alzheimer's disease, Parkinson's disease, and pain. It operates through the Infrastructure Business and Life Sciences segments. The Infrastructure Business segment involves the rental of heavy construction equipment, execution of construction contracts, and purchase and reseal of physical commodities used in infrastructure. The Life Sciences segment includes a biotech component, and a vertically integrated hemp-cannabinoid based healthcare and wellness business, which involves the production of plant and cannabinoid-based products, and therapies. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

alzheimer parkinson construction alzheimer’s

Drugs

Hyalolex Hand Sanitizer (ALCOHOL)
Hyalolex Hand Sanitizer with Lemon and Zinc (ALCOHOL)

add to watch list Paper trade email alert is off

INmune Bio Inc.

INMB | News | $10.615 26.82% 21.15% 680K

Health Technology

(0.0% 1d) (-9.2% 1m) (40.1% 1y) (0.0% 2d) (0.0% 3d) (26.1% 7d) (Infinity% volume)
Earnings Calendar: 2024-04-01
Market Cap: $ 193,229,017
http://www.inmunebio.com
Sec Filling | Patents | 4 employees

INmune Bio, Inc. focuses on controlling components of the immune system to activate an immune response against cancer and Alzheimer’s disease. Its product pipeline INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer, and LIVNATE. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.

cancer alzheimer alzheimer’s

add to watch list Paper trade email alert is off

Intra-Cellular Therapies Inc.

ITCI | $74.58 3.05% 2.96% 1.9M

Health Technology

(0.0% 1d) (9.7% 1m) (19.7% 1y) (0.0% 2d) (0.0% 3d) (-4.4% 7d) (-11.94% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 7,219,880,305
http://www.intracellulartherapies.com
Sec Filling | Patents | 330 employees

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.

neurodegenerative schizophrenia glass alzheimer heavy drug nervous system neuropsychiatric molecule drugs neurological msa treatment alzheimer’s

add to watch list Paper trade email alert is off

Cassava Sciences, Inc.

SAVA M | $20.54 4.58% 4.38% 770K

Health Technology

(0.0% 1d) (4.1% 1m) (-10.2% 1y) (0.0% 2d) (0.0% 3d) (-3.6% 7d) (-41.77% volume)
Earnings Calendar: 2024-02-28
Market Cap: $ 888,267,869
http://www.cassavasciences.com
Sec Filling | Patents | 9 employees

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

alzheimer diagnostics treatment alzheimer’s

add to watch list Paper trade email alert is off